Jing Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jing Tan has a total of 388 co-authors. Here are the top co-authors by number of shared publications:
- Jason Yongsheng Chan
Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
13 shared publications Jing Han Hong
13 shared publicationsPeili Wang
13 shared publications- Bin Tean Teh
Cancer and Stem Cell Biology Programme, Duke-NUS Medical School, Singapore 169857, Singapore
12 shared publications Jianfeng Chen
Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China
12 shared publications- Peiyong Guan
Genome Institute of Singapore, Singapore, Singapore
12 shared publications
Latest Publications
- 30 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (124)
Nuclear NAD + promotes innate immune memory by inhibiting KDM5A-dependent histone demethylation
Trained immunity is tightly regulated by metabolic and epigenetic reprogramming, yet how these changes are orchestrated at the chromatin level to establish long-term innate immune memory is not fully understood. Here, we show that induction of trained immunity elevates nuclear levels of nicotinamide adenine dinucleotide (NAD + ), which directly binds to KDM5A demethylase and inhibits its activity, thereby sustaining H3K4me3 (histone H3 lysine 4 trimethylation) levels and chromatin accessibility at inflammatory gene promoters to enhance “memory” responsiveness upon restimulation. Genetic deletion or pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme for NAD + synthesis, impaired trained immunity and associated antitumor activity. Nicotinamide mononucleotide (NMN) supplementation rescued defective trained immunity–mediated antitumor activity in NAMPT-deficient and aged mice. In human cancer, NAMPT expression in myeloid cells correlated with an inflammatory tumor microenvironment. Our findings identify KDM5A as a nuclear NAD + sensor that orchestrates histone methylation and chromatin accessibility required for trained immunity.
- 30 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (124)
Nuclear NAD + promotes innate immune memory by inhibiting KDM5A-dependent histone demethylation
Trained immunity is tightly regulated by metabolic and epigenetic reprogramming, yet how these changes are orchestrated at the chromatin level to establish long-term innate immune memory is not fully understood. Here, we show that induction of trained immunity elevates nuclear levels of nicotinamide adenine dinucleotide (NAD + ), which directly binds to KDM5A demethylase and inhibits its activity, thereby sustaining H3K4me3 (histone H3 lysine 4 trimethylation) levels and chromatin accessibility at inflammatory gene promoters to enhance “memory” responsiveness upon restimulation. Genetic deletion or pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme for NAD + synthesis, impaired trained immunity and associated antitumor activity. Nicotinamide mononucleotide (NMN) supplementation rescued defective trained immunity–mediated antitumor activity in NAMPT-deficient and aged mice. In human cancer, NAMPT expression in myeloid cells correlated with an inflammatory tumor microenvironment. Our findings identify KDM5A as a nuclear NAD + sensor that orchestrates histone methylation and chromatin accessibility required for trained immunity.
- 21 October 2026
- Published by Elsevier in Cancer Letters
- Vol. 663
Targeting CDC7 overcomes gemcitabine resistance in cholangiocarcinoma by inducing cellular senescence
- 21 October 2026
- Published by Elsevier in Cancer Letters
- Vol. 663
Targeting CDC7 overcomes gemcitabine resistance in cholangiocarcinoma by inducing cellular senescence
- Open Access
- 12 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Targeting MDA5 induces immunogenic cell death and promotes anti-tumor immunity
- 12 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessTargeting MDA5 induces immunogenic cell death and promotes anti-tumor immunity
- Open Access
- 2 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Mevalonate pathway rewiring driven by enhancer remodelling confers resistance to KRAS inhibitors in colorectal cancer
KRAS inhibitors (KRASi) have emerged as promising new cancer therapeutics for KRAS-mutant cancers; however, resistance remains a potential clinical challenge. Here, we show that reactivation of ERK is a hallmark of KRASi-resistant colorectal cancers (CRCs) and further demonstrate that enhancer remodeling rewires cholesterol biosynthesis through the mevalonate (MVA) pathway to confer this resistance. Mechanistically, enhancer remodeling activates MVA pathway, which facilitates the trafficking of KRAS to the membrane and sustains the MAPK signaling despite KRAS inhibition. Pharmacological inhibition of the MVA pathway with statins effectively blocks KRAS localization to the cell membrane, overcoming KRASi resistance in CRC. Together, these findings identify epigenetic-metabolic coupling of cholesterol biosynthesis as a mechanism of KRASi resistance and highlight targetable metabolic vulnerability in KRAS-mutant CRC.
- 2 June 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessMevalonate pathway rewiring driven by enhancer remodelling confers resistance to KRAS inhibitors in colorectal cancer
KRAS inhibitors (KRASi) have emerged as promising new cancer therapeutics for KRAS-mutant cancers; however, resistance remains a potential clinical challenge. Here, we show that reactivation of ERK is a hallmark of KRASi-resistant colorectal cancers (CRCs) and further demonstrate that enhancer remodeling rewires cholesterol biosynthesis through the mevalonate (MVA) pathway to confer this resistance. Mechanistically, enhancer remodeling activates MVA pathway, which facilitates the trafficking of KRAS to the membrane and sustains the MAPK signaling despite KRAS inhibition. Pharmacological inhibition of the MVA pathway with statins effectively blocks KRAS localization to the cell membrane, overcoming KRASi resistance in CRC. Together, these findings identify epigenetic-metabolic coupling of cholesterol biosynthesis as a mechanism of KRASi resistance and highlight targetable metabolic vulnerability in KRAS-mutant CRC.
- 1 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (843) , eadr6668
Uncovering BAP1 deubiquitination landscape enhances mechanism elucidation and therapeutic precision for BAP1-deficient pancancers
Inactivating mutations in BAP1 (BRCA1-associated protein 1) are prevalent in many aggressive cancers of high global concern, including cholangiocarcinoma, mesothelioma, uveal melanoma, and renal cell carcinoma. However, research on BAP1 has been predominantly focused on single cancer types, lacking comprehensive pancancer studies that could uncover universal molecular mechanisms and therapeutic vulnerabilities. Our pancancer study uses K-ε-GG ubiquitin remnant motif pulldown coupled with mass spectrometry to comprehensively map the landscape of proteins deubiquitinated by BAP1. Combined with transcriptomics and functional assays, we uncover previously unrecognized roles of BAP1 in enhancing global genome nucleotide excision repair (GG-NER) by modulating the deubiquitination dynamics of three GG-NER DNA damage recognition proteins, DDB1, RAD23B, and COPS7B. We also identify LSD1 (lysine-specific histone demethylase 1) and PARP1 [poly(ADP-ribose) polymerase 1] as synthetic lethal partners of BAP1 through high-throughput drug inhibitor screening. Integrative analysis using ChIP sequencing, ATAC sequencing, and transcriptomics demonstrates the colocalization of BAP1, LSD1, and PARP1 on chromatin loci, with LSD1 promoting chromatin relaxation to facilitate efficient transcription-coupled NER (TC-NER) in addition to GG-NER, whereas PARP1 facilitates lesion recognition of both TC-NER and GG-NER. Combined inhibition of LSD1 and PARP1, using SP2509/SP2577 and olaparib, respectively, synergistically hinders NER, induces apoptosis, reduces tumor burden, and prolongs the survival of multiple BAP1-deficient pancancer in vitro models and in vivo xenografts. In conclusion, our results provide a deubiquitination landscape of BAP1; elucidate the mechanisms of action of BAP1, LSD1, and PARP1 in pancancers; and describe a promising combination therapeutic strategy applicable across multiple cancers with BAP1 mutations.
- 1 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (843) , eadr6668
Uncovering BAP1 deubiquitination landscape enhances mechanism elucidation and therapeutic precision for BAP1-deficient pancancers
Inactivating mutations in BAP1 (BRCA1-associated protein 1) are prevalent in many aggressive cancers of high global concern, including cholangiocarcinoma, mesothelioma, uveal melanoma, and renal cell carcinoma. However, research on BAP1 has been predominantly focused on single cancer types, lacking comprehensive pancancer studies that could uncover universal molecular mechanisms and therapeutic vulnerabilities. Our pancancer study uses K-ε-GG ubiquitin remnant motif pulldown coupled with mass spectrometry to comprehensively map the landscape of proteins deubiquitinated by BAP1. Combined with transcriptomics and functional assays, we uncover previously unrecognized roles of BAP1 in enhancing global genome nucleotide excision repair (GG-NER) by modulating the deubiquitination dynamics of three GG-NER DNA damage recognition proteins, DDB1, RAD23B, and COPS7B. We also identify LSD1 (lysine-specific histone demethylase 1) and PARP1 [poly(ADP-ribose) polymerase 1] as synthetic lethal partners of BAP1 through high-throughput drug inhibitor screening. Integrative analysis using ChIP sequencing, ATAC sequencing, and transcriptomics demonstrates the colocalization of BAP1, LSD1, and PARP1 on chromatin loci, with LSD1 promoting chromatin relaxation to facilitate efficient transcription-coupled NER (TC-NER) in addition to GG-NER, whereas PARP1 facilitates lesion recognition of both TC-NER and GG-NER. Combined inhibition of LSD1 and PARP1, using SP2509/SP2577 and olaparib, respectively, synergistically hinders NER, induces apoptosis, reduces tumor burden, and prolongs the survival of multiple BAP1-deficient pancancer in vitro models and in vivo xenografts. In conclusion, our results provide a deubiquitination landscape of BAP1; elucidate the mechanisms of action of BAP1, LSD1, and PARP1 in pancancers; and describe a promising combination therapeutic strategy applicable across multiple cancers with BAP1 mutations.
- Open Access
- 9 January 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1) , 19
PRMT5 upregulates KCNMB4 expression via histone methylation to promote paclitaxel resistance in advanced nasopharyngeal carcinoma
Concurrent chemotherapy is the standard treatment strategy for advanced-stage nasopharyngeal carcinoma (NPC). However, chemoresistance inevitable develops and the underlying mechanism remains poorly understood. In this study, we identify the arginine methyltransferase PRMT5 as a key gene associated with chemoresistance to paclitaxel in NPC. We demonstrate that PRMT5 facilitated paclitaxel resistance by inducing KCNMB4 expression in nasopharyngeal carcinoma cells. Mechanistically, PRMT5 is recruited to the promoter region of KCNMB4, where it catalyzes H3R2me2s and enhances KCNMB4 expression. Furthermore, elevated levels of PRMT5 or KCNMB4 correlated with poorer survival and higher recurrence rates in NPC patients. Notably, genetic or pharmacological inhibition of PRMT5 significantly sensitized NPC cells to paclitaxel, both in vitro and in vivo. Collectively, these results suggest that the PRMT5-KCNMB4 axis plays a crucial role in mediating chemoresistance in NPC and targeting this axis may provide a promising therapeutic strategy for late-stage NPC patients.
- 9 January 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1) , 19
Open AccessPRMT5 upregulates KCNMB4 expression via histone methylation to promote paclitaxel resistance in advanced nasopharyngeal carcinoma
Concurrent chemotherapy is the standard treatment strategy for advanced-stage nasopharyngeal carcinoma (NPC). However, chemoresistance inevitable develops and the underlying mechanism remains poorly understood. In this study, we identify the arginine methyltransferase PRMT5 as a key gene associated with chemoresistance to paclitaxel in NPC. We demonstrate that PRMT5 facilitated paclitaxel resistance by inducing KCNMB4 expression in nasopharyngeal carcinoma cells. Mechanistically, PRMT5 is recruited to the promoter region of KCNMB4, where it catalyzes H3R2me2s and enhances KCNMB4 expression. Furthermore, elevated levels of PRMT5 or KCNMB4 correlated with poorer survival and higher recurrence rates in NPC patients. Notably, genetic or pharmacological inhibition of PRMT5 significantly sensitized NPC cells to paclitaxel, both in vitro and in vivo. Collectively, these results suggest that the PRMT5-KCNMB4 axis plays a crucial role in mediating chemoresistance in NPC and targeting this axis may provide a promising therapeutic strategy for late-stage NPC patients.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Data from Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma
Anti–PD-1 immunotherapy has demonstrated significant antitumor efficacy in relapsed or refractory NK/T-cell lymphoma (R/R NKTL), but resistance remains a substantial challenge. In this study, we evaluate DNA methyltransferase (DNMT) inhibitors combined with anti–PD-1 mAb in 21 patients with R/R NKTL for whom prior immunotherapy failed. This combination therapy achieved an objective response rate of 66.7% (14/21), with a complete response rate of 47.6% (10/21) and a 2-year overall survival rate of 50.2%. Preclinical models revealed that anti–PD-1 resistance was linked to the absence of CD8+ T-cell infiltration and suppressed IFN pathways. DNMT inhibitors reversed these effects, restoring CD8+ T-cell activities and tumor sensitivity to PD-1 blockade. Mechanistically, DNMT inhibitors triggered DNA demethylation of endogenous retroviral elements, activating viral mimicry via upregulated endogenous nucleic acids and type I IFN signaling. These findings underscore DNMT inhibitors’ role in overcoming PD-1 resistance and support their combination with anti–PD-1 as a promising strategy for R/R NKTL.Significance:Resistance to anti–PD-1 immunotherapy remains a substantial challenge in R/R NKTL. In this study, we reported that combining DNMT inhibitors with anti–PD-1 mAb achieves a high complete response rate of 47.6% in immunotherapy-R/R NKTL patients. Mechanistically, DNMT inhibitors potentiate anti–PD-1 efficacy by triggering viral mimicry, remodeling the immune microenvironment and augmenting antitumor immunity.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma
Anti–PD-1 immunotherapy has demonstrated significant antitumor efficacy in relapsed or refractory NK/T-cell lymphoma (R/R NKTL), but resistance remains a substantial challenge. In this study, we evaluate DNA methyltransferase (DNMT) inhibitors combined with anti–PD-1 mAb in 21 patients with R/R NKTL for whom prior immunotherapy failed. This combination therapy achieved an objective response rate of 66.7% (14/21), with a complete response rate of 47.6% (10/21) and a 2-year overall survival rate of 50.2%. Preclinical models revealed that anti–PD-1 resistance was linked to the absence of CD8+ T-cell infiltration and suppressed IFN pathways. DNMT inhibitors reversed these effects, restoring CD8+ T-cell activities and tumor sensitivity to PD-1 blockade. Mechanistically, DNMT inhibitors triggered DNA demethylation of endogenous retroviral elements, activating viral mimicry via upregulated endogenous nucleic acids and type I IFN signaling. These findings underscore DNMT inhibitors’ role in overcoming PD-1 resistance and support their combination with anti–PD-1 as a promising strategy for R/R NKTL.Significance:Resistance to anti–PD-1 immunotherapy remains a substantial challenge in R/R NKTL. In this study, we reported that combining DNMT inhibitors with anti–PD-1 mAb achieves a high complete response rate of 47.6% in immunotherapy-R/R NKTL patients. Mechanistically, DNMT inhibitors potentiate anti–PD-1 efficacy by triggering viral mimicry, remodeling the immune microenvironment and augmenting antitumor immunity.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S4 from Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma
Supplementary Table S1 Table S1 Prior ICB treatment information of patients. Supplementary Table S2 Baseline characteristics of patients. Supplementary Table S3 Primers for DNA methylation analysis. Supplementary Table S4 Primers for RT-qPCR.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S4 from Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma
Supplementary Table S1 Table S1 Prior ICB treatment information of patients. Supplementary Table S2 Baseline characteristics of patients. Supplementary Table S3 Primers for DNA methylation analysis. Supplementary Table S4 Primers for RT-qPCR.
- Open Access
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-12 from Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma
Supplementary Figure S1. Tumor-infiltrating CD8+ cell was positive correlation to efficacy of the combined DNMT inhibition and anti-PD-1 mAb therapy. Supplementary Figure S2. No significant reduction in body weight of EL4 tumor-bearing mice with anti-PD-1 treatment. Supplementary Figure S3. Gating strategies for Figure 2D-F. Supplementary Figure S4. PD-L1 and PD-1 expression in pre-clinical models. Supplementary Figure S5. Immune related pathways were downregulated in EL4 P3 tumor. Supplementary Figure S6. No significant reduction in body weight of EL4 P3 tumor-bearing mice under different treatment. Supplementary Figure S7. DNMT inhibitors enhance CD8+ T cell activated and cytotoxicity in vivo. Supplementary Figure S8. DNMT inhibitors treatment did not affect PD-L1 expression in pre-clinical models. Supplementary Figure S9. DNMT inhibitors induce MHC-I and ISGs expression in EL4 cells. Supplementary Figure S10. IFNAR1 blockade attenuated the antitumor immunity induced by the combination of DAC and α-PD-1. Supplementary Figure S11. STING knockdown did not impair DNMT inhibitors induced CD8+ T cells activity. Supplementary Figure S12. DNMT inhibitors induces ERVs expression in human NKTL cells.
- 2 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-12 from Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma
Supplementary Figure S1. Tumor-infiltrating CD8+ cell was positive correlation to efficacy of the combined DNMT inhibition and anti-PD-1 mAb therapy. Supplementary Figure S2. No significant reduction in body weight of EL4 tumor-bearing mice with anti-PD-1 treatment. Supplementary Figure S3. Gating strategies for Figure 2D-F. Supplementary Figure S4. PD-L1 and PD-1 expression in pre-clinical models. Supplementary Figure S5. Immune related pathways were downregulated in EL4 P3 tumor. Supplementary Figure S6. No significant reduction in body weight of EL4 P3 tumor-bearing mice under different treatment. Supplementary Figure S7. DNMT inhibitors enhance CD8+ T cell activated and cytotoxicity in vivo. Supplementary Figure S8. DNMT inhibitors treatment did not affect PD-L1 expression in pre-clinical models. Supplementary Figure S9. DNMT inhibitors induce MHC-I and ISGs expression in EL4 cells. Supplementary Figure S10. IFNAR1 blockade attenuated the antitumor immunity induced by the combination of DAC and α-PD-1. Supplementary Figure S11. STING knockdown did not impair DNMT inhibitors induced CD8+ T cells activity. Supplementary Figure S12. DNMT inhibitors induces ERVs expression in human NKTL cells.
- Open Access
- 28 November 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1683550
Synergistic anti-tumor activity of the mTOR inhibitor everolimus and gemcitabine for relapsed/refractory peripheral T cell lymphoma
Background: Relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) patients face poor prognosis and limited therapies. The mTOR inhibitor everolimus and gemcitabine show modest efficacy as single agents in R/R PTCL, warranting investigation of combination regimens. Methods: This study conducted a single-center retrospective analysis of 24 patients diagnosed with peripheral T-cell lymphoma, aged 18 to 70 years, who experienced relapse or refractory disease following at least one first-line chemotherapy regimen, and received treatment at Guangdong Provincial People’s Hospital between December 2017 and March 2021. CellTiter Glo and AnnexinV FITC/PI assays evaluated cell viability and apoptosis in vitro . Results: The combination showed significant efficacy: objective response rate (ORR) 70.8%, complete response (CR) rate 45.8%, median time to response 1.7 months. With median follow-up of 22.3 months (95% CI 5.7–39.0), median progression-free survival (PFS) was 9.9 months (95% CI 0–20.81), and median duration of response (DOR) 16.8 months. Patients with CR/partial response (PR) had longer PFS (18.7 vs. 1.2 months, P = 0.0007) and overall survival (OS) (30.9 vs. 5.8 months, P = 0.021) than those with stable/progressive disease. RNA-seq results showed that the combined therapeutic approach synergistically reduces cell viability and promotes apoptosis through the inhibition of the MYC signaling pathway. Conclusion: Everolimus-gemcitabine combination exhibits synergistic antitumor activity, offering a potential therapeutic strategy for R/R PTCL.
- 28 November 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1683550
Open AccessSynergistic anti-tumor activity of the mTOR inhibitor everolimus and gemcitabine for relapsed/refractory peripheral T cell lymphoma
Background: Relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) patients face poor prognosis and limited therapies. The mTOR inhibitor everolimus and gemcitabine show modest efficacy as single agents in R/R PTCL, warranting investigation of combination regimens. Methods: This study conducted a single-center retrospective analysis of 24 patients diagnosed with peripheral T-cell lymphoma, aged 18 to 70 years, who experienced relapse or refractory disease following at least one first-line chemotherapy regimen, and received treatment at Guangdong Provincial People’s Hospital between December 2017 and March 2021. CellTiter Glo and AnnexinV FITC/PI assays evaluated cell viability and apoptosis in vitro . Results: The combination showed significant efficacy: objective response rate (ORR) 70.8%, complete response (CR) rate 45.8%, median time to response 1.7 months. With median follow-up of 22.3 months (95% CI 5.7–39.0), median progression-free survival (PFS) was 9.9 months (95% CI 0–20.81), and median duration of response (DOR) 16.8 months. Patients with CR/partial response (PR) had longer PFS (18.7 vs. 1.2 months, P = 0.0007) and overall survival (OS) (30.9 vs. 5.8 months, P = 0.021) than those with stable/progressive disease. RNA-seq results showed that the combined therapeutic approach synergistically reduces cell viability and promotes apoptosis through the inhibition of the MYC signaling pathway. Conclusion: Everolimus-gemcitabine combination exhibits synergistic antitumor activity, offering a potential therapeutic strategy for R/R PTCL.